- Home
- JHI vs HLVX Comparison
JHI vs HLVX Comparison
Compare JHI & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- HLVX
- Stock Information
- Founded
- JHI 1971
- HLVX 2020
- Country
- JHI United States
- HLVX United States
- Employees
- JHI N/A
- HLVX N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- JHI Finance
- HLVX Health Care
- Exchange
- JHI Nasdaq
- HLVX Nasdaq
- Market Cap
- JHI 125.7M
- HLVX 104.3M
- IPO Year
- JHI N/A
- HLVX 2022
- Fundamental
- Price
- JHI $14.22
- HLVX $2.09
- Analyst Decision
- JHI
- HLVX Hold
- Analyst Count
- JHI 0
- HLVX 1
- Target Price
- JHI N/A
- HLVX $2.00
- AVG Volume (30 Days)
- JHI 29.5K
- HLVX 930.2K
- Earning Date
- JHI 01-01-0001
- HLVX 11-06-2025
- Dividend Yield
- JHI 6.80%
- HLVX N/A
- EPS Growth
- JHI N/A
- HLVX N/A
- EPS
- JHI 1.05
- HLVX N/A
- Revenue
- JHI N/A
- HLVX N/A
- Revenue This Year
- JHI N/A
- HLVX N/A
- Revenue Next Year
- JHI N/A
- HLVX N/A
- P/E Ratio
- JHI $12.47
- HLVX N/A
- Revenue Growth
- JHI N/A
- HLVX N/A
- 52 Week Low
- JHI $11.63
- HLVX $1.34
- 52 Week High
- JHI $13.40
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- JHI 51.62
- HLVX 51.28
- Support Level
- JHI $14.14
- HLVX $2.07
- Resistance Level
- JHI $14.46
- HLVX $2.11
- Average True Range (ATR)
- JHI 0.12
- HLVX 0.02
- MACD
- JHI -0.01
- HLVX -0.00
- Stochastic Oscillator
- JHI 30.95
- HLVX 50.00
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.